cobimetinib
Sign in to saveAlso known as GDC-0973, XL-518, XL518, GDC 0973, RG 7420, Xl 518, RG7420, GDC0973
Cobimetinib, sold under the brand name Cotellic, is an anti-cancer medication used to treat melanoma and histiocytic neoplasms. Cobimetinib is a MEK inhibitor. Cobimetinib is marketed by Genentech.
Wikidata facts
- Mass
- 531.063
- Has use
- medication
Show 6 more facts
- chemical formula
- C₂₁H₂₁F₃IN₃O₂
- isomeric SMILES
- C1CCN[C@@H](C1)C2(CN(C2)C(=O)C3=C(C(=C(C=C3)F)F)NC4=C(C=C(C=C4)I)F)O
- canonical SMILES
- C1CCNC(C1)C2(CN(C2)C(=O)C3=C(C(=C(C=C3)F)F)NC4=C(C=C(C=C4)I)F)O
- World Health Organisation international non-proprietary name
- cobimetinib
- subject has role
- protein kinase inhibitors
- medical condition treated
- melanoma
via Wikidata · CC0
~3 min read
Encyclopedic overview
5 sectionsContents
- Medical use
- Adverse effects
- History
- Research
- References
Cobimetinib, sold under the brand name Cotellic, is an anti-cancer medication used to treat melanoma and histiocytic neoplasms. Cobimetinib is a MEK inhibitor. Cobimetinib is marketed by Genentech.
The most common side effects include diarrhea, rash, nausea (feeling sick), vomiting, pyrexia (fever), photosensitivity (light sensitivity) reaction, abnormal results for certain liver function tests (increased levels of alanine aminotransferase, aspartate aminotransferase) and abnormal results for an enzyme related to muscle breakdown (creatine phosphokinase).
Excerpted from Wikipedia’s “cobimetinib” article, available under the CC BY-SA 4.0 licence.